Page 239 - Binder2

These aren’t speculative use cases.
They are already in development—and plant-based
platforms are making them feasible at scale, for the first
time.

Tolerizing vaccines are not a workaround.
They are the immune system’s native language—spoken
fluently, biologically, and orally.

And with plant-based delivery, we finally have a platform
that knows how to say the right thing.

Table: Clinical and Preclinical Programs in
Edible Tolerizing Vaccines

Indicatio Antigen Plant Study Key Example /
n Delivered Platform Type Findings Reference
Reduced islet Daniell et al.,
Preclinic infiltration; Biomaterials,
Insulin / al (NOD increased 2014;
Type 1 Lettuce /
Diabetes proinsulin Rice mice), Tregs; ClinicalTrials.g
peptides Early preservation ov
Clinical of beta-cell NCT02715555
function (oral insulin)
Reduced
clinical
severity; Ma et al.,
Myelin decreased Nature
basic Preclinic CNS Biotechnology,
Multiple Tobacco /
Sclerosis protein Lettuce al (EAE inflammation 2013; oral MBP
(MBP) models) ; mucosal delivery in
peptides induction of lettuce and
FoxP3⁺ tobacco
regulatory T
cells

237